Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianjun Zou

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
Cancer Communications (London, England)|November 4, 2022
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapyFengying Wu, Tao Jiang, Gongyan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III TrialNing Li, Youzhong Zhang, Jing Wang, et al.
Journal of Hematology & Oncology|February 26, 2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Thrombosis and Haemostasis : JTH|November 25, 2021
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension studyHeng Mei, Xiaofan Liu, Yan Li, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
Cancer Communications (London, England)|November 4, 2022
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapyFengying Wu, Tao Jiang, Gongyan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III TrialNing Li, Youzhong Zhang, Jing Wang, et al.
Journal of Hematology & Oncology|February 26, 2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Thrombosis and Haemostasis : JTH|November 25, 2021
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension studyHeng Mei, Xiaofan Liu, Yan Li, et al.
Pageof 20